{"description":"Documents matching 'Pharmacy Compounding Advisory Committee'","count":452,"total_pages":23,"next_page_url":"https://www.federalregister.gov/api/v1/documents?conditions%5Bterm%5D=Pharmacy+Compounding+Advisory+Committee&format=json&page=2","results":[{"title":"Advisory Committee; Pharmacy Compounding Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Pharmacy Compounding Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Pharmacy Compounding Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the April 25, 2028, expiration date.","document_number":"2026-08378","html_url":"https://www.federalregister.gov/documents/2026/04/30/2026-08378/advisory-committee-pharmacy-compounding-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-04-30/pdf/2026-08378.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-08378.pdf?1777466710","publication_date":"2026-04-30","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-charter \n or by contacting the Advisory Committee Oversight and Management Staff (see \n FOR FURTHER INFORMATION CONTACT \n ). In light of the fact that no change has been made to the committee name or description of duties, no amendment will be made to 21 CFR 14.100.\n \n \n This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app.). For general information related to FDA advisory committees, \n \n please visit us"},{"title":"Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List","type":"Notice","abstract":"The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Pharmacy Compounding Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.","document_number":"2026-07361","html_url":"https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-04-16/pdf/2026-07361.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-07361.pdf?1776257113","publication_date":"2026-04-16","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"ACTION: \n Notice; establishment of a public docket; request for comments. \n \n \n SUMMARY: \n The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Pharmacy Compounding Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document. \n \n \n DATES: \n The meeting will be held on July 23, 2026, from 8:00 a.m. to 4:30 p.m"},{"title":"Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances","type":"Notice","abstract":"The Secretary of the Department of Health and Human Services (HHS) is announcing the availability of an \"Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.\" This document describes the Secretary of HHS's enforcement policy regarding the use of certain peptide bulk drug substances in compounding pursuant to section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) while the list of bulk drug substances that can be used in compounding under section 503A of the FD&C Act (the 503A bulks list) is developed through rulemaking.","document_number":"2026-22192","html_url":"https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-30/pdf/2026-22192.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-22192.pdf?1793200509","publication_date":"2026-10-30","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"}],"excerpts":"tailored to the needs of an individual patient. Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed. Although compounded drugs can serve an important medical need for certain patients, they also may pose risks to patients. However, based on the Pharmacy Compounding Advisory Committee meetings and data regarding utilization of peptides, HHS believes that there is significant interest in the use of these peptides in compounding given the lack of availability of approved"},{"title":"Advisory Committee; Pharmacy Compounding Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Pharmacy Compounding Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Pharmacy Compounding Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the April 25, 2026, expiration date.","document_number":"2024-16667","html_url":"https://www.federalregister.gov/documents/2024/07/30/2024-16667/advisory-committee-pharmacy-compounding-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-07-30/pdf/2024-16667.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-16667.pdf?1722257121","publication_date":"2024-07-30","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Federal advisory committee. \n \n \n SUMMARY: \n The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Pharmacy Compounding Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Pharmacy Compounding Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the April 25, 2026, expiration date. \n \n \n DATES: \n Authority for the Pharmacy Compounding Advisory Committee"},{"title":"Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List","type":"Notice","abstract":"The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Pharmacy Compounding Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.","document_number":"2024-24828","html_url":"https://www.federalregister.gov/documents/2024/10/25/2024-24828/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-10-25/pdf/2024-24828.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-24828.pdf?1729773929","publication_date":"2024-10-25","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"ACTION: \n Notice; establishment of a public docket; request for comments. \n \n \n SUMMARY: \n The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Pharmacy Compounding Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document. \n \n \n DATES: \n The meeting will be held on December 4, 2024, from 8 a.m. to 3 p.m. Eastern"},{"title":"Advisory Committee; Antimicrobial Drugs Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Antimicrobial Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Antimicrobial Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the October 7, 2028, expiration date.","document_number":"2026-20142","html_url":"https://www.federalregister.gov/documents/2026/10/01/2026-20142/advisory-committee-antimicrobial-drugs-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-01/pdf/2026-20142.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20142.pdf?1790712911","publication_date":"2026-10-01","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Metabolic Drugs Advisory Committee \n • Genetic Metabolic Diseases Advisory Committee \n • Medical Devices Advisory Committee \n • National Mammography Quality Assurance Advisory Committee (Administratively Inactive) \n • Nonprescription Drugs Advisory Committee \n • Obstetrics, Reproductive and Urologic Drugs Advisory Committee \n • Oncologic Drugs Advisory Committee \n • Pediatric Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • Psychopharmacologic Drugs Advisory Committee \n • Pulmonary-Allergy"},{"title":"Advisory Committee; Psychopharmacologic Drugs Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Psychopharmacologic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Psychopharmacologic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the June 4, 2028, expiration date.","document_number":"2026-10674","html_url":"https://www.federalregister.gov/documents/2026/05/29/2026-10674/advisory-committee-psychopharmacologic-drugs-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-29/pdf/2026-10674.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-10674.pdf?1779972313","publication_date":"2026-05-29","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Management Advisory Committee \n ○ Endocrinologic and Metabolic Drugs Advisory Committee \n ○ Gastrointestinal Drugs Advisory Committee \n ○ Genetic and Metabolic Disease Advisory Committee \n ○ Medical Devices Advisory Committee \n ○ National Mammography Quality Assurance Advisory Committee (Administratively Inactive) \n ○ Nonprescription Drugs Advisory Committee \n ○ Obstetrics Reproductive and Urologic Drugs Advisory Committee \n ○ Oncologic Drugs Advisory Committee \n ○ Patient Engagement Advisory Committee \n ○ Pediatrics Advisory Committee \n ○ Peripheral"},{"title":"Advisory Committee; Pulmonary-Allergy Drugs Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Pulmonary-Allergy Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Pulmonary- Allergy Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the May 30, 2028, expiration date.","document_number":"2026-10410","html_url":"https://www.federalregister.gov/documents/2026/05/26/2026-10410/advisory-committee-pulmonary-allergy-drugs-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-26/pdf/2026-10410.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-10410.pdf?1779453918","publication_date":"2026-05-26","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Management Advisory Committee \n • Endocrinologic and Metabolic Drugs Advisory Committee \n • Gastrointestinal Drugs Advisory Committee \n • Genetic and Metabolic Disease Advisory Committee \n • Medical Devices Advisory Committee \n • National Mammography Quality Assurance Advisory Committee (Administratively Inactive) \n • Nonprescription Drugs Advisory Committee \n • Obstetrics, Reproductive and Urologic Drugs Advisory Committee \n • Oncologic Drugs Advisory Committee \n • Patient Engagement Advisory Committee \n • Pediatrics Advisory Committee \n • Peripheral"},{"title":"Advisory Committee; Peripheral and Central Nervous System Drugs Advisory Committee; Termination and Reestablishment","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the termination and reestablishment of the Peripheral and Central Nervous System Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Peripheral and Central Nervous System Drugs Advisory Committee was terminated on June 4, 2026, because its charter was not renewed on or before that expiration date. The Commissioner has determined that it is in the public interest to reestablish the Peripheral and Central Nervous System Drugs Advisory Committee for 2 years from the date it is reestablished.","document_number":"2026-14829","html_url":"https://www.federalregister.gov/documents/2026/07/23/2026-14829/advisory-committee-peripheral-and-central-nervous-system-drugs-advisory-committee-termination-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-07-23/pdf/2026-14829.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-14829.pdf?1784724308","publication_date":"2026-07-23","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Management Advisory Committee \n • Endocrinologic and Metabolic Drugs Advisory Committee \n • Genetic Metabolic Diseases Advisory Committee \n • Medical Devices Advisory Committee \n • National Mammography Quality Assurance Advisory Committee (Administratively Inactive) \n • Nonprescription Drugs Advisory Committee \n • Obstetrics, Reproductive and Urologic Drugs Advisory Committee \n • Oncologic Drugs Advisory Committee \n • Pediatric Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • Psychopharmacologic Drugs Advisory Committee \n • Pulmonary-Allergy"},{"title":"Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Cardiovascular and Renal Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Cardiovascular and Renal Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the August 27, 2028, expiration date.","document_number":"2026-16999","html_url":"https://www.federalregister.gov/documents/2026/08/20/2026-16999/advisory-committee-cardiovascular-and-renal-drugs-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-20/pdf/2026-16999.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16999.pdf?1787143523","publication_date":"2026-08-20","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Metabolic Drugs Advisory Committee \n • Genetic Metabolic Disease Advisory Committee \n • Medical Devices Advisory Committee \n • National Mammography Quality Assurance Advisory Committee (Administratively Inactive) \n • Nonprescription Drugs Advisory Committee \n • Obstetrics, Reproductive and Urologic Drugs Advisory Committee \n • Oncologic Drugs Advisory Committee \n • Pediatric Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • Psychopharmacologic Drugs Advisory Committee \n • Pulmonary-Allergy"},{"title":"Advisory Committee; Gastrointestinal Drugs Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Gastrointestinal Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Gastrointestinal Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the March 3, 2028, expiration date.","document_number":"2026-03587","html_url":"https://www.federalregister.gov/documents/2026/02/24/2026-03587/advisory-committee-gastrointestinal-drugs-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-02-24/pdf/2026-03587.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-03587.pdf?1771854307","publication_date":"2026-02-24","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Health Advisory Committee \n • Drug Safety and Risk Management Advisory Committee \n • Endocrinologic and Metabolic Drugs Advisory Committee \n • Genetic and Metabolic Disease Advisory Committee \n • Medical Devices Advisory Committee \n • National Mammography Quality Assurance Advisory Committee (Administratively Inactive) \n • Nonprescription Drugs Advisory Committee \n • Obstetrics, Reproductive and Urologic Drugs Advisory Committee \n • Oncologic Drugs Advisory Committee \n \n • Patient Engagement Advisory Committee\n \n \n • Pediatrics Advisory Committee"},{"title":"Advisory Committee; Obstetrics, Reproductive and Urologic Drugs Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Obstetrics, Reproductive and Urologic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Obstetrics, Reproductive and Urologic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the March 23, 2028, expiration date.","document_number":"2026-05313","html_url":"https://www.federalregister.gov/documents/2026/03/18/2026-05313/advisory-committee-obstetrics-reproductive-and-urologic-drugs-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-03-18/pdf/2026-05313.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-05313.pdf?1773751518","publication_date":"2026-03-18","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Health Advisory Committee \n • Drug Safety and Risk Management Advisory Committee \n • Endocrinologic and Metabolic Drugs Advisory Committee \n • Gastrointestinal Drugs Advisory Committee \n • Genetic and Metabolic Disease Advisory Committee \n • Medical Devices Advisory Committee \n • National Mammography Quality Assurance Advisory Committee (Administratively Inactive) \n • Nonprescription Drugs Advisory Committee \n • Oncologic Drugs Advisory Committee \n • Patient Engagement Advisory Committee \n • Pediatrics Advisory Committee \n • Peripheral and Central"},{"title":"Advisory Committee; Dermatologic and Ophthalmic Drugs Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Dermatologic and Ophthalmic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Dermatologic and Ophthalmic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the October 7, 2028, expiration date.","document_number":"2026-20141","html_url":"https://www.federalregister.gov/documents/2026/10/01/2026-20141/advisory-committee-dermatologic-and-ophthalmic-drugs-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-01/pdf/2026-20141.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20141.pdf?1790712911","publication_date":"2026-10-01","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Devices Advisory Committee \n • National Mammography Quality Assurance Advisory Committee (Administratively Inactive) \n • Nonprescription Drugs Advisory Committee \n • Obstetrics, Reproductive and Urologic Drugs Advisory Committee \n • Oncologic Drugs Advisory Committee \n • Pediatric Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • Psychopharmacologic Drugs Advisory Committee \n • Pulmonary-Allergy Drugs Advisory Committee \n • Risk Communication Advisory Committee (Administratively"},{"title":"Advisory Committee; Anesthetic and Analgesic Drug Products Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Anesthetic and Analgesic Drug Products Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Anesthetic and Analgesic Drug Products Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the May 1, 2028, expiration date.","document_number":"2026-08125","html_url":"https://www.federalregister.gov/documents/2026/04/27/2026-08125/advisory-committee-anesthetic-and-analgesic-drug-products-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-04-27/pdf/2026-08125.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-08125.pdf?1777034709","publication_date":"2026-04-27","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Metabolic Disease Advisory Committee \n • Medical Devices Advisory Committee \n • National Mammography Quality Assurance Advisory Committee (Administratively Inactive) \n • Nonprescription Drugs Advisory Committee \n • Obstetrics, Reproductive and Urologic Drugs Advisory Committee \n • Oncologic Drugs Advisory Committee \n • Patient Engagement Advisory Committee \n • Pediatrics Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • Psychopharmacologic Drugs Advisory Committee \n • Pulmonary-Allergy"},{"title":"Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List","type":"Notice","abstract":"The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Pharmacy Compounding Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.","document_number":"2024-21241","html_url":"https://www.federalregister.gov/documents/2024/09/18/2024-21241/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-09-18/pdf/2024-21241.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-21241.pdf?1726577134","publication_date":"2024-09-18","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"ACTION: \n Notice; establishment of a public docket; request for comments. \n \n \n SUMMARY: \n The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Pharmacy Compounding Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document. \n \n \n DATES: \n The meeting will be held on October 29, 2024, from 8 a.m. to 5 p.m. eastern"},{"title":"Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Endocrinologic and Metabolic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Endocrinologic and Metabolic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the August 27, 2028, expiration date.","document_number":"2026-16998","html_url":"https://www.federalregister.gov/documents/2026/08/20/2026-16998/advisory-committee-endocrinologic-and-metabolic-drugs-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-20/pdf/2026-16998.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16998.pdf?1787143523","publication_date":"2026-08-20","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Metabolic Drugs Advisory Committee \n • Genetic Metabolic Disease Advisory Committee \n • Medical Devices Advisory Committee \n • National Mammography Quality Assurance Advisory Committee (Administratively Inactive) \n • Nonprescription Drugs Advisory Committee \n • Obstetrics, Reproductive and Urologic Drugs Advisory Committee \n • Oncologic Drugs Advisory Committee \n • Pediatric Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • Psychopharmacologic Drugs Advisory Committee \n • Pulmonary-Allergy"},{"title":"Advisory Committee; Blood Products Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Blood Products Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Blood Products Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the May 13, 2028, expiration date.","document_number":"2026-09108","html_url":"https://www.federalregister.gov/documents/2026/05/07/2026-09108/advisory-committee-blood-products-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-07/pdf/2026-09108.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-09108.pdf?1778071535","publication_date":"2026-05-07","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"and Metabolic Disease Advisory Committee \n • Medical Devices Advisory Committee \n • National Mammography Quality Assurance Advisory Committee (Administratively Inactive) \n • Nonprescription Drugs Advisory Committee \n • Obstetrics, Reproductive and Urologic Drug Advisory Committee \n \n • Oncologic Drugs Advisory Committee \n \n \n • Patient Engagement Advisory Committee \n • Pediatrics Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • Pharmacy Compounding Drugs AC \n • Psychopharmacologic"},{"title":"Advisory Committee; Cellular, Tissue, and Gene Therapies Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Cellular, Tissue, and Gene Therapies Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Cellular, Tissue, and Gene Therapies Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the October 28, 2028, expiration date.","document_number":"2026-20989","html_url":"https://www.federalregister.gov/documents/2026/10/14/2026-20989/advisory-committee-cellular-tissue-and-gene-therapies-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-14/pdf/2026-20989.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20989.pdf?1791895521","publication_date":"2026-10-14","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Devices Advisory Committee \n • National Mammography Quality Assurance Advisory Committee (Administratively Inactive) \n \n • Nonprescription Drugs Advisory Committee\n \n \n • Obstetrics, Reproductive and Urologic Drugs Advisory Committee \n • Oncologic Drugs Advisory Committee \n • Pediatric Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • Psychopharmacologic Drugs Advisory Committee \n • Pulmonary-Allergy Drugs Advisory Committee \n • Risk Communication Advisory Committee (Administratively"},{"title":"Advisory Committee; Science Board to the Food and Drug Administration; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Science Board to the Food and Drug Administration by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Science Board to the Food and Drug Administration for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the June 26, 2028, expiration date.","document_number":"2026-12235","html_url":"https://www.federalregister.gov/documents/2026/06/18/2026-12235/advisory-committee-science-board-to-the-food-and-drug-administration-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-06-18/pdf/2026-12235.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-12235.pdf?1781700309","publication_date":"2026-06-18","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Drugs Advisory Committee \n Genetic and Metabolic Disease Advisory Committee \n Medical Devices Advisory Committee \n National Mammography Quality Assurance Advisory Committee (Administratively Inactive) \n Nonprescription Drugs Advisory Committee \n Oncologic Drugs Advisory Committee \n Patient Engagement Advisory Committee \n Pediatrics Advisory Committee \n Peripheral and Central Nervous System Advisory Committee \n Pharmacy Compounding Advisory Committee \n Psychopharmacologic Drugs Advisory Committee \n Pulmonary-Allergy Drugs Advisory Committee \n Risk"},{"title":"Advisory Committee; Drug Safety and Risk Management Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Drug Safety and Risk Management Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Drug Safety and Risk Management Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the May 31, 2028, expiration date.","document_number":"2026-10371","html_url":"https://www.federalregister.gov/documents/2026/05/26/2026-10371/advisory-committee-drug-safety-and-risk-management-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-26/pdf/2026-10371.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-10371.pdf?1779453911","publication_date":"2026-05-26","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Metabolic Drugs Advisory Committee \n • Gastrointestinal Drugs Advisory Committee \n • Genetic and Metabolic Disease Advisory Committee \n • Medical Devices Advisory Committee \n • National Mammography Quality Assurance Advisory Committee (Administratively Inactive) \n • Nonprescription Drugs Advisory Committee \n • Oncologic Drugs Advisory Committee \n • Patient Engagement Advisory Committee \n • Pediatrics Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • Pharmacy Compounding Drugs AC"}]}